HK 메이저 바카라.N and Pfizer Korea enter distribution and co-promotion partnership for COVID-19 Vaccine

[by Lee, Young Sung] HK inno.N announced on September 4 that it had entered into a co-promotion agreement with Pfizer Korea on August 27 for the 2025-2026 season's new COVID-19 variant vaccine, ‘Comirnaty® LP.8.1 Prefilled Syringe (SARS-CoV-2 mRNA Vaccine),’ and held a signing ceremony to commemorate the occasion.

The signing ceremony, which took place at HK 메이저 바카라.N Square, was attended by HK 메이저 바카라.N CEO Kwak Dal-won, Pfizer Korea Country Manager Dave (Dong-wook) Oh, and senior executives from both companies.

In 2024, HK 메이저 바카라.N managed the distribution of Comirnaty JN.1 Injection (single-dose, bretovameran; SARS-CoV-2 mRNA vaccine) to the private market. More recently, the company has overseen the distribution of vaccines valued at around KRW 200 billion (approximately USD 143.4 million) under the National Immunization Program, targeting high-risk groups (elderly people aged 65 and older and immunocompromised patients).

Through this co-promotion agreement, HK 메이저 바카라.N and Pfizer Korea have further strengthened their partnership, extending it to encompass promotional activities within the scope of the National Immunization Program.

Comirnaty® LP.8.1 Prefilled Syringe received approval from the Ministry of Food and Drug Safety on March 29 for the prevention of COVID-19 caused by the SARS-CoV-2 virus in children aged 12 years and older. The vaccine is administered as a single 0.3 mL intramuscular injection, irrespective of prior COVID-19 vaccination status. For those previously vaccinated, administration is recommended at least three months following the most recent dose.

"We are honored to expand this co-promotion agreement to the National Immunization Program, building on our prior role in private distribution and national immunization initiatives. By leveraging our sales and distribution expertise, we will ensure a stable supply of Comirnaty® LP.8.1 Prefilled Syringe and contribute to the improvement of public health," expressed Kwak Dal-won, CEO of HK inno.N.

"We are honored to broaden our collaboration with HK inno.N, an organization with extensive experience and experience in vaccine distribution, to include distribution and co-promotion of the National Immunization Program," said Dave (Dong-wook) Oh, Country Manager of Pfizer Korea.

"Pfizer Korea remains committed to ensuring a stable supply of COVID-19 vaccines, thereby safeguarding high-risk populations, particularly individuals aged 65 and older and those with compromised immune systems. We will also continue our efforts to fulfill our mission of delivering 'innovations that transform patients' lives,'" Oh, further commented.